Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators.

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
2.

Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.

Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L.

Eur Heart J. 2004 Nov;25(22):1990-7.

3.

The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.

Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J; Euro Heart Survey Investigators.

Eur Heart J. 2004 Nov;25(21):1880-90.

4.

Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia.

Borch-Johnsen K, Colagiuri S, Balkau B, Glümer C, Carstensen B, Ramachandran A, Dong Y, Gao W.

Diabetologia. 2004 Aug;47(8):1396-402. Epub 2004 Jul 24.

PMID:
15278279
5.
6.

Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic?

Schriger DL, Lorber B.

Diabetes Care. 2004 Feb;27(2):592-601. No abstract available.

PMID:
14747244
7.

IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.

Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM; IFCC Working Group on HbA1c Standardization.

Clin Chem. 2004 Jan;50(1):166-74.

8.

Diagnosis and classification of diabetes mellitus.

American Diabetes Association.

Diabetes Care. 2004 Jan;27 Suppl 1:S5-S10. No abstract available.

PMID:
14693921
9.

Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes.

Tenerz A, Norhammar A, Silveira A, Hamsten A, Nilsson G, Rydén L, Malmberg K.

Diabetes Care. 2003 Oct;26(10):2770-6.

PMID:
14514578
10.

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.

JAMA. 2003 Jul 23;290(4):486-94.

PMID:
12876091
11.

Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

DECODE Study Group, European Diabetes Epidemiology Group.

Diabetes Care. 2003 Mar;26(3):688-96.

PMID:
12610023
12.

Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography.

Taubert G, Winkelmann BR, Schleiffer T, März W, Winkler R, Gök R, Klein B, Schneider S, Boehm BO.

Am Heart J. 2003 Feb;145(2):285-91.

PMID:
12595846
13.

Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study.

Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K.

Lancet. 2002 Jun 22;359(9324):2140-4.

PMID:
12090978
14.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.

N Engl J Med. 2002 Feb 7;346(6):393-403.

15.

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group.

N Engl J Med. 2001 May 3;344(18):1343-50.

16.

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

DECODE Study Group, the European Diabetes Epidemiology Group..

Arch Intern Med. 2001 Feb 12;161(3):397-405.

PMID:
11176766
17.

Abnormal glucose tolerance, not small vessel diameter, is a determinant of long-term prognosis in patients treated with balloon coronary angioplasty.

Otsuka Y, Miyazaki S, Okumura H, Yasuda S, Daikoku S, Morii I, Sutani Y, Goto Y, Nonogi H.

Eur Heart J. 2000 Nov;21(21):1790-6.

19.
20.

Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria.

Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ.

Lancet. 1999 Aug 21;354(9179):622-5.

PMID:
10466662
Items per page

Supplemental Content

Write to the Help Desk